GFM
VOR icon

GF Fund Management’s Vor Biopharma VOR Stock Holding History

GF Fund Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7K Buy
1,072
+700
+188% +$10.6K ﹤0.01% 482
2026
Q1 		$6.64K Buy
372
+42
+13% +$592 ﹤0.01% 591
2025
Q4 		$4.32K Buy
+330
New +$6.14K ﹤0.01% 626

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

GF Fund Management's VOR Position: Q2 2026 in Review

GF Fund Management increased its Vor Biopharma (VOR) stake by 188% in Q2 2026, buying an estimated $10.6K and bringing the position to 1,072 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #482.

GF Fund Management first reported a position in VOR in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • GF Fund Management held 1,072 shares of Vor Biopharma worth $19.7K as of Q2 2026.
  • GF Fund Management bought 700 Vor Biopharma shares in Q2 2026, an estimated $10.6K.
  • Vor Biopharma made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #482 holding.
  • GF Fund Management first reported a position in Vor Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.